Overview and Scope
Nuclear medicine radioisotopes are radioactive isotopes used in nuclear medicine to diagnose, treat, and research various medical conditions. These isotopes emit radiation detected and imaged by specialized equipment or deliver therapeutic doses of radiation to targeted tissues. Nuclear medicine radioisotopes are essential in modern medical diagnostics and treatments, providing critical information and therapeutic options that improve patient outcomes.
Sizing and Forecast
The nuclear medicine radioisotopes market size has grown strongly in recent years. It will grow from $7.57 billion in 2023 to $8.21 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to discovery of radioactivity, emergence of nuclear medicine, therapeutic applications, clinical research, and patient demand.
The nuclear medicine radioisotopes market size is expected to see strong growth in the next few years. It will grow to $11.44 billion in 2028 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing healthcare spending, expansion of healthcare infrastructure, growing awareness of environmental sustainability, education campaigns and awareness programs and growth in medical tourism. Major trends in the forecast period include development of new radioisotopes, production and supply chain innovations, microfluidics and lab-on-a-chip technology, artificial intelligence in radiopharmaceutical development and nanotechnology.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/nuclear-medicine-radioisotopes-global-market-report
Segmentation & Regional Insights
The nuclear medicine radioisotopes market covered in this report is segmented –
1) By Type: Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Iodine (I-123), Fluorine-18, Rubidium-82 (Rb-82), Iodine-131 (I-131), Lutetium-177 (Lu-177), Radium-223 (Ra-223) And Alpharadin, Actinium-225 (Ac-225), Other Types
2) By Application: Oncology, Cardiology, Thyroid, Neurology, Other Applications
3) By End-User: Hospitals, Diagnostic Centers, Specialty Clinics, Education And Research Institutes, Other End-Users
North America was the largest region in the nuclear medicine radioisotopes market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16132&type=smp
Major Driver Impacting Market Growth
The rising cases of cardiovascular diseases are expected to propel the growth of the nuclear medicine radioisotope market going forward. Cardiovascular diseases refer to a group of diseases that affect the heart and blood vessels. The rising cases of cardiovascular diseases are due to sedentary lifestyles, poor dietary habits, increasing rates of obesity, and aging populations. The nuclear medicine radioisotopes are invaluable in diagnosing, evaluating, and managing cardiovascular diseases with detailed insights into cardiac function, perfusion, and tissue viability, which are essential for accurate diagnosis and effective treatment planning. For instance, in May 2022, according to the Centers for Disease Control and Prevention, a US-based governmental organization, the prevalence of coronary heart disease among adults aged 18 and over stood at 4.6% in 2020, experiencing a slight uptick to 4.9% in 2021. Therefore, the rising cases of cardiovascular diseases are driving the growth of the nuclear medicine radioisotope market.
Key Industry Players
Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer Aktiengesellschaft, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., Eczacıbaşı-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation
The nuclear medicine radioisotopes market report table of contents includes:
1. Executive Summary
2. Nuclear Medicine Radioisotopes Market Characteristics
3. Nuclear Medicine Radioisotopes Market Trends And Strategies
4. Nuclear Medicine Radioisotopes Market – Macro Economic Scenario
5. Global Nuclear Medicine Radioisotopes Market Size and Growth
.
.
.
32. Global Nuclear Medicine Radioisotopes Market Competitive Benchmarking
33. Global Nuclear Medicine Radioisotopes Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Nuclear Medicine Radioisotopes Market
35. Nuclear Medicine Radioisotopes Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
